Navigation Links
Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting

Forward-looking statements

Some of the statements in this press release are forward looking. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Merck Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements are based on Merck Serono’s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on February 28, 2006. These factors include any failure or delay in Merck Serono’s ability to develop new products, any failure to receive anticipated regulatory approvals, any problems in commercializing current products as a result of competition or other factors, our ability to obtain reimbursement coverage for our products, the outcome of any government investigations and litigation. Merck Serono is providing this information as of the date of this press release, and has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.

###

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono S.A., which has the rights to develop the compound in PD, Alzheimer´s disease, other cognitive disorders and Restless Legs Syndrome. Recent results
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
2. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
3. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
4. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
5. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/23/2013)... SAINT PAUL, Minn. , May 23, 2013 /PRNewswire/ ... Angeion Corporation), a global medical technology company, today scheduled ... the second quarter of fiscal year 2013, ended April ... ET on Thursday, May 30, 2013. The Company will ... year 2013 after the markets close on Thursday, May ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
(Date:5/23/2013)... Calif. , May 23, 2013 Anthem ... program that would have required them to obtain their ... by Consumer Watchdog and Whatley Kallas LLC.  ... Superior Court, alleged that Blue Cross,s mandatory mail order ... threatening their health and privacy. "This settlement ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
... A Commonwealth Fund case study notes that ... aligned "to launch innovations and organize services in ways that make ... study -- along other profiles looking at medical systems that have ... high performing health care system -- has been in the works ...
... Conatus Pharmaceuticals Inc. announced today the initiation of a ... for the treatment of liver disease associated with Hepatitis C ... treatment with approved standard of care treatments is not currently ... patients who failed standard of care treatment are expected to ...
Cached Medicine Technology:Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 2Commonwealth Fund Case Study Points to 'Continuous Innovation' at Group Health Cooperative 3Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis 2
(Date:5/25/2013)... According to an article in the June ... nearly 30 million Americans tan indoors each year and an ... knowing the health risks. New research suggests that UV ... on the brains of some tanners (Go to goo.gl/hdwnz). ... I can’t say that I fully support this contention from ...
(Date:5/25/2013)... An experienced Chandler dentist has just launched ... Media Surge, LLC. , http://www.ChandlerDentalExcellence.com/Teeth-Whitening.php , ... on the treatment, can be performed in the office ... method will be chosen for the individual patient. , ... special peroxide-based whitening gel is used along with a ...
(Date:5/25/2013)... -- Many viruses and parasites that affect both dogs ... bacteria-borne illness than can result in liver or kidney ... to a veterinarian. These germs could be ... said Dr. Susan Nelson, a clinical associate professor at ... serious diseases can be fatal, even with treatment," she ...
(Date:5/25/2013)... Providing patients with their best weight loss is the ... professionals. But, aside from educating patients on how to ... diets also provide patients, who have gained weight because ... control over their lives by achieving their best weight loss. ... of weight gain derived from earlier abuse, Diet Doc's ...
(Date:5/25/2013)... By working diligently for months on ... of the 2012 Lamborghini Aventador into their well-built fitments ... in the list of vehicles lined by SizeItUp for ... set to thrill automobile lovers in the year 2013. ... looks, the 2012 Lamborghini Aventador comes with extraordinarily spacious ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Chandler Dentist Launches Teeth Whitening Service Page on Website in Partnership with JD Media Surge, LLC 2Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces hCG Diet Plans for Those Suffering from Abuse-Related Weight Gain 3Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2
... Doxorubicin (DOX) is a red-colored anticancer drug that ... cardiac muscle deterioration (cardiomyopathy) and scar tissue accumulation ... due to inhibition by DOX of mitochondrial biogenesis, ... In a new study by Claude Piantadosi and ...
... a steroid slows progress of multiple myeloma, an incurable ... who have relapsed from previous treatment, researchers report in ... In the study conducted at 44 centers in the ... either a combination of lenalidomide (Revlimid(r)) and the steroid ...
... trials show "unprecedented" survival for patients with multiple myeloma, ... of bone marrow. The findings demonstrate that with Revlimid, ... significant improvement in patients where previous treatments had failed. ... study. Results of the study were published November 21 ...
... Smith brings free, national weight-loss initiative to Big Easy; Urges residents to ... ... Church, NEW ORLEANS, Nov. 21 Dr. ... to take control of their,health and give up the pounds to fight the ...
... Nov. 21 The following was issued,today by the ... talking, but he still isn,t saying,what he would do ... rest of,the Republican presidential candidates, his current rhetoric focuses ... an approach he,once said could not work. But, as ...
... Universal,Health Services, Inc. (NYSE: UHS ) announced today ... dividend of $0.08 per share on December 17,2007 to ... Universal Health Services, Inc. is one of the nation,s ... and,ambulatory centers nationwide and in Puerto Rico., Certain ...
Cached Medicine News:Health News:Drug combination effective against multiple myeloma, researchers show 2Health News:Drug combination effective against multiple myeloma, researchers show 3Health News:Oral drug sets a new survival standard for bone marrow cancer 2Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 2Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 3Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 4Health News:DNC: Romney's Health Care Confusion Continues 2Health News:DNC: Romney's Health Care Confusion Continues 3
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... optical performance of the OMEGA 180, the ... better views of the fundus. A new ... Xenon Halogen Technology bulb produce less reflexes ... images of the fundus that are up ...
... The New 2.2 Fr Sur-Catch NT stone retrieval ... new level. Its unique paired wire design ... adjusts to the needs of each patient and ... designed specifically for use with the DURTM-8 Elite ...
Medicine Products: